2-(4-((5,6-diphenylpyrazin-2-yl)(isopropyl)amino)butoxy)-N-(methylsulfonyl)acetamide,
ACT 293987,
ACT-293987,
ACT293987,
NS-304,
selexipag,
Uptravi,
Selexipag,
NS-304,
475086-01-2,
Uptravi,
NS 304,
ACT-293987,
UNII-5EXC0E384L,
ACT 293987,
5EXC0E384L,
2-(4-((5,6-diphenylpyrazin-2-yl)(isopropyl)amino)butoxy)-N-(methylsulfonyl)acetamide,
2-(4-((5,6-Diphenylpyrazin-2-yl)(propan-2-yl)amino)butoxy}-n-(methanesulfonyl)acetamide,
2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide,
Selexipag [USAN:INN],
2-{4-[(5,6-diphenylpyrazin-2-yl)(propan-2-yl)amino]butoxy}-N-(methanesulfonyl)acetamide,
Uptravi (TN),
NS-304(Selexipag),
Selexipag(NS-304),
Selexipag (JAN/USAN/INN),
SCHEMBL674122,
CHEMBL238804,
GTPL7552,
CHEBI:90844,
CTK8F0123,
QXWZQTURMXZVHJ-UHFFFAOYSA-N,
BCP09146,
ZINC3990451,
3938AH,
MFCD10567093,
AKOS024457572,
CS-3774,
DB11362,
SB17055,
KS-00000L89,
NCGC00370833-01,
AC-30209,
AK298890,
HY-14870,
RT-014761,
B7378,
D09994,
144383-EP2289518A1,
144383-EP2292231A1,
2-(4-((5,6-Diphenylpyrazinyl)(1-methylethyl)amino)butoxy)-N-(methylsulfonyl)-acetamide,
2-[4-[(5,6-Diphenyl-2-pyrazinyl)(1-methylethyl)amino]butoxy]-N-(methylsulfonyl)acetamide,
2-[4-[(5,6-diphenylpyrazin-2-yl)-propan-2-ylamino]butoxy]-N-methylsulfonylacetamide,
2-[4-[[5,6-di(phenyl)pyrazin-2-yl]-propan-2-ylamino]butoxy]-N-methylsulfonylacetamide,
2-{4-[(5,6-diphenylpyrazin-2-yl)(propan-2-yl)amino]butoxy}-N-methanesulfonylacetamide,
D0N2SR,
C26H32N4O4S,
ACT293987,
CID9913767,
A13880,
2-[4-[(5,6-diphenylpyrazin-2-yl)-propan-2-yl-amino]butoxy]-N-methylsulfonyl-acetamide,
2-{4-[(5,6-Diphenyl-2-Pyrazinyl)(Isopropyl)Amino]Butoxy}-N-(Methylsulfonyl)Acetamide,